Abstract:DISCLAIMER In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE Proton pump inhibitors (PPIs) are widely prescribed medications. Various adverse clinical effects of PPIs have been reported in the literature, particularly over the past decade. The purpose of this article is to review published data primarily describing adverse effects associated with PPI use and to help clinicians determine which patients may still benefit from therapy despite safety concerns. SUMMARY Associations between PPIs and the following have been described: bone fracture, acute and chronic kidney disease, gastrointestinal infections, deficiencies in vitamin B12 and magnesium, and coronavirus disease 2019 and respiratory infections. For inclusion in this review, studies must have evaluated potential adverse events associated with PPIs as a primary or secondary objective. Increased risks of bone fracture, acute and chronic kidney disease, gastrointestinal infections, and magnesium deficiency were consistently reported, albeit mostly in studies involving low-quality data (case-control and/or observational studies) and subject to bias. In the only pertinent randomized controlled trial to date, chronic pantoprazole use was associated with a greater risk of enteric infections relative to placebo use; there was no significant between-group difference in any other adverse event evaluated. PPIs continue to be recommended by the American College of Gastroenterology as a first-line treatment for management of gastroesophageal reflux disease and in the acute period following upper gastrointestinal and ulcer bleeding. CONCLUSION Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.

Adverse Reaction of Proton Pump Inhibitors and Development of its New Formulation

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

Focus on Safety of Proton Pump Inhibitors

Research Progress and Clinical Use of Proton Pump Inhibitors

Studies of Proton Pump Inhibitors and Tumor Resistance to Antitumor Drugs

25 Years of Proton Pump Inhibitors: A Comprehensive Review

Adverse reactions of proton pump inhibitors

Retrospective Comments on Prescriptions of Oral Proton Pump Inhibitors for Outpatients in A General Hospital

Current situation of progress in long-term use of proton pump inhibitors may increase the risk of dementia

Proton Pump Inhibitors: Review of Emerging Concerns

Sequelae of Hypergastrinemia Due to Long-Term Administration of Proton Pump Inhibitors and Its Management

Proton pump inhibitors from clinical pharmacists point of view

The current views focused on clinical application of proton pump inhibitors

Analysis of side effects of long-term PPIs therapy

Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers

Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors

Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.

Clinical Application of Proton Pump Inhibitors

Proton Pump Inhibitors and Oral–Gut Microbiota: From Mechanism to Clinical Significance

Long Term Risks of Proton Pump Inhibitor Administration: A Literature Review

Proton pump inhibitors are not associated with fundic gland polyps – a systematic review that takes into consideration all known confounders